Skip to content
Company Analysis

MaxCyte, Inc. MXCT

A comprehensive view of key metrics, scores, and financial health for MaxCyte, Inc.

Overview of MaxCyte, Inc.

MXCT NMS
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Micro Cap
MaxCyte, Inc. (MXCT), is a Micro Cap company, in the Medical Devices industry, last closed at $1.12, about 0.0% overvalued vs fair value, -49.1% 1Y return, ranked 781/1122 in sector.
USD 1.12
1.82%
(Delayed)
• Vol 90d: 73.4%
52-Week Range
Market Cap
$123.19M
Enterprise Value
$126.12M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 70%
Confidence: 83%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.maxcyte.com
HQ Rockville, MD
Employees 114
Fiscal year Dec 31

Next Events

Earnings Aug 12 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $1.12

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$33.0M
-14.5%%
Gross Profit
$26.8M
-15%%
Operating Income (GAAP)
$-45.3M
11.5%%
EBITDA
$-40.1M
13.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
81.2%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$459.0K

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating MaxCyte, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
44
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Strong
77
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing MXCT's balance between Growth (28.2%), Profitability (44.0%), and Safety (27.8%). Growth 28% Safety 28% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

29th percentile vs peers
29
Key Signals
Revenue CAGR 3Y 4.5% 43p Rev Growth YoY -6.4% 19p EPS Growth YoY -6.6% 28p Asset Growth YoY -10.7% 29p
Strengths
  • Gross Profit Margin in top 20% of peers (81.6%, 91th percentile)
  • Equity/Assets in top 20% of peers (86.1%, 89th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-6.4%)

Profitability

45th percentile vs peers
45
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

28th percentile vs peers
29
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for MaxCyte, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.19
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000